Rationale for evaluating PDE4 inhibition for mitigating against severe inflammation in COVID-19 pneumonia and beyond

Charlie Bridgewood, Giovanni Damiani, Kassem Sharif, Abdulla Watad, Nicola Luigi Bragazzi, Luca Quartuccio, Sinisa Savic, Dennis McGonagle

Research output: Contribution to journalReview articlepeer-review

Abstract

In the absence of definitive anti-viral therapy, there is considerable interest in mitigating against severe inflammatory reactions in coronavirus disease-2019 (COVID-19) pneumonia to improve survival. These reactions are sometimes termed cytokine storm. PDE4 inhibitors (PDE4i) have anti-inflammatory properties with approved indications in inflammatory skin and joint diseases as well as chronic obstructive pulmonary disease. Furthermore, multiple animal models demonstrate strong anti-inflammatory effects of PDE4i in respiratory models of viral and bacterial infection and also after chemically mediated lung injury. The rationale for PDE4i use in COVID-19 patients comes from the multimodal mechanism of action with cytokine, chemokine, and other key pathway inhibition all achieved with an excellent safety profile. The authors highlight how PDE4i could be an overlooked treatment from the rheumatologic and respiratory armamentarium, which has potential beneficial immune-modulation for treating severe COVID-19 pneumonia associated with cytokine storms. The proposed use of PDE4i is also supported by age-related immune changes in inflammation severity in PDE4i modifiable pathways in primate coronavirus disease. Over-exuberant anti-viral immune responses in older patients with COVID-19 may pose a substantial risk to patient survival and mitigation against such hyper-inflammation with PDE4i, especially with anti-viral agents, is a strategy that need to be pursed, especially in older patients.

Original languageEnglish
Pages (from-to)335-339
Number of pages5
JournalIsrael Medical Association Journal
Volume22
Issue number6
Publication statusPublished - Jun 2020
Externally publishedYes

Keywords

  • Apremilast
  • Coronavirus disease-2019 (COVID-19)
  • Cytokines
  • Lung
  • Phosphodiesterase 4 inhibitors (PDE4i)

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Rationale for evaluating PDE4 inhibition for mitigating against severe inflammation in COVID-19 pneumonia and beyond'. Together they form a unique fingerprint.

Cite this